

# **26<sup>th</sup> Young Research Fellows Meeting**

**Faculty of Pharmacy  
Paris  
February, 20<sup>th</sup>-22<sup>nd</sup>, 2019**

I

# POSTER ABSTRACT

# Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3 $\beta$ inhibitors

**Bezsonova E.N. #1<sup>(1)\*</sup>, Lozinskaya N.A. #2<sup>(1,2)</sup>, Zaryanova E.V. #3<sup>(1)</sup>, Tsymlyakov M.D. #4<sup>(1)</sup>, Efremov A.M. #5<sup>(1)</sup>, Anikina L.V. #6<sup>(2)</sup>, Babkov D.A. #7<sup>(3)</sup>, Zakharyasheva O. Yu. #8<sup>(3)</sup>, Prilepskaya D.R. #9<sup>(3)</sup>, Spasov A.A. #10<sup>(3)</sup>, Proskurnina M.V. #11<sup>(1,2)</sup>**


*(1) Lomonosov Moscow State University, Department of Chemistry, Leniskie Gory St., 1, Moscow, 119234, Russia*

*(2) Institute of Physiologically Active Compounds, Russian Academy of Sciences, 1 Severniy Avenue, 142432, Chernogolovka, Moscow Region, Russia*

*(3) Research Institute of Pharmacology, Volgograd State Medical University, KIM St. 20, 400001, Volgograd, Russia*

PO 020

A number of novel glycogen synthase kinase 3 $\beta$  (GSK-3 $\beta$ ) inhibitors with promising activity were synthesized using the 3-arylidene-2-oxindole scaffold. The lead compound (**1**) was shown to inhibit GSK-3 $\beta$  with IC<sub>50</sub> 4.19 nM. with moderate cytotoxicity in a cell-based assay. Compound **1** was evaluated in oral glucose tolerance test in rat model of type 2 diabetes mellitus and demonstrated significant antidiabetic effect. The results attest to the potential for further development of **1** as a therapeutic agent for treatment of diabetes<sup>1,2</sup> and cancer<sup>3,4</sup>.



Compound	R	Ar	Yield %	% Inhibition at 10 $\mu$ M	IC <sub>50</sub> ( $\mu$ M)
<b>1</b>	H	2-pyridyl	79	95.70	0.00419
<b>2</b>	BzNH	4-OH-Ph	99	58.94	4.343
<b>3</b>	CH <sub>3</sub> C(O)NH	3,4,5-tri-MeO-Ph	43	84.16	0.2329
<b>4</b>	MeOC(O)NH	4-OH-Ph	44	91.82	0.1554
<b>5</b>	MeOC(O)NH	4-NO <sub>2</sub> -Ph	49	69.29	0.3479

## Bibliographic references:

- Biochemical Pharmacology*, 2013, Vol. 86, no 2, P. 191-199.
- Diabetes*, 2002, Vol. 51, no 10, P.2903-2910.
- Molecular Carcinogenesis*, 2017, Vol. 56, no 10, P. 2301-2316.
- ACS Chemical Biology*, 2014, Vol. 9, no 2, P.353-358.

Acknowledgments: This work was supported by the Russian Foundation for Basic Research (Project 17-03-01320)

\* Correspondence: E-mail [zetsu45999@mail.ru](mailto:zetsu45999@mail.ru)